Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II study of pazopanib in metastatic merkel cell carcinoma

Next Previous
X
Search
Trial Profile

A Phase II study of pazopanib in metastatic merkel cell carcinoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms UKMCC01

    • Most Recent Events

    • 07 Jun 2016 Status changed from recruiting to discontinued as the primary endpoint of was met and the accrual was very slow, according to the Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Primary endpoint (Clinical response rate measured by RECIST) has been met, according to the Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top